期刊名称：International Journal of Health Policy and Management
电子版ISSN：2322-5939
出版年度：2020
卷号：9
期号：12
页码：528-530
DOI：10.15171/ijhpm.2020.03
出版社：Kerman University of Medical Sciences
摘要：The movement for a national pharmacare plan in Canada is growing, but at the same time the multinational pharmaceutical companies and their supporters are critical of such a move. The three major arguments that they make are that all that is needed is to “fill in the gaps,” ie, cover those who currently are uninsured or underinsured, that private drug plans are superior to public ones because they cover a larger number of drugs and that Canada cannot afford pharmacare. This commentary examines each of these arguments and makes the case that none of them is valid and that it is time to get on with implementing pharmacare.
关键词：Canada ; Drug Expenditures ; Formulary ; Pharmacare ; Pharmaceutical Industry
